Climb Bio Inc CLYM

US Biotechnology

$11.67 ▲ +5.99% (+$0.66)

⬆️ Above Yest. High 🔥 High Short Interest

Open $10.88

Prev Close $11.01

Day Range $10.62 – $11.85

52W Range $1.64 – $18.33

Market Cap $646.71M

Beta 0.10

EPS (TTM) $-0.82

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-08-10
Shares Out.	57,440,000
Website	climbbio.com/ ↗
Phone	13026365400
Employees	29
Revenue	$0
Gross Profit	$0
Net Income	-$15.0M
Free Cash Flow	-$53.6M
Total Assets	$236.6M
Total Liabilities	$8.5M
Equity	$228.1M

About Climb Bio Inc

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Climb Bio Inc is a publicly traded company under the ticker symbol CLYM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.